BioCentury | Mar 27, 2019
Product Development

GW’s next act

As Epidiolex’s launch continues to ramp up, GW Pharmaceuticals’ next act will be to take the plunge with its cannabinoid platform into larger, more complex neurobehavioral indications, and even cancer. Not surprisingly, the rise of...
BC Week In Review | Dec 8, 2017
Company News

Therapix gains rights to synthetic cannabinoids from Hebrew University

Therapix Biosciences Ltd. (Tel Aviv:TRPX; NASDAQ:TRPX) received non-exclusive rights to IP for two synthetic cannabinoid compounds from Yissum Research Development Company Ltd., the Hebrew University of Jerusalem's technology transfer arm. Therapix said Yissum retains ownership...
BC Innovations | Feb 2, 2017
Translation in Brief

New high for cannabinoids

A consortium of academic and industry scientists have joined forces to help separate the signal from the noise in translational studies of the cannabinoid CB2 receptor (CNR2) by benchmarking the 18 most commonly used agonists...
BC Week In Review | Jul 14, 2014
Company News

Cortex Pharmaceuticals Inc, University of Illinois deal

Cortex received exclusive, worldwide rights from the university to patents covering the use of cannabinoids to treat sleep-related breathing disorders. Cortex’s dronabinol, a cannabinol agonist, is in a Phase II trial conducted by the university...
BC Innovations | Dec 8, 2011
Targets & Mechanisms

FLATtening pain

Italian and Californian researchers have discovered a protein called FAAH-like anandamide transporter that helps inactivate the endocannabinoid signaling molecule anandamide, a naturally occurring analgesic. 1 The team has created a small molecule antagonist of the...
BC Week In Review | Oct 11, 2010
Clinical News

Cannabinoids: Phase IIa started

GW began a double-blind, placebo-controlled Phase IIa trial to evaluate 4 undisclosed cannabinoid formulations in 50 Type II diabetics for 13 weeks. GW Pharmaceuticals plc (LSE:GWP), Salisbury, U.K.   Product: Cannabinoids   Business: Metabolic  ...
BC Week In Review | Nov 2, 2009
Company News

Roche, Hebrew University of Jerusalem deal

The university's Yissum Ltd. tech transfer arm granted Roche options to license exclusive, worldwide rights to develop and commercialize resulting technologies from six of the university's programs following completion of the research phase. The programs...
BC Innovations | Mar 26, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Addiction; pain Fatty acid binding protein 5 brain (FABP5); FABP7 In vitro studies suggest that inhibiting FABPs could increase endocannabinoid...
BC Innovations | Jan 31, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cervical cancer; lung cancer Cannabinoid CB1 receptor; cannabinoid CB2 receptor In vitro studies suggest that palliative cannabinoids could treat some invasive...
BioCentury | Jul 11, 2005
Product Development

Keys to cannabinoid success

Cannabinoids are thought to be useful in CNS disorders because they modulate neurotransmission and calcium homeostasis, as well as having anti-inflammatory and antioxidant actions. But as with other applications of the class, the problem has...
Items per page:
1 - 10 of 17